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Next generation sequencing has revolutionised genomic studies of cancer, having facilitated the 
development of precision oncology treatments based on a tumour’s molecular profile. We aimed to 
develop a targeted gene sequencing panel for application to disparate cancer types with particular 
focus on tumours of the head and neck, plus test for utility in liquid biopsy. The final panel designed 
through Roche/Nimblegen combined 451 cancer-associated genes (2.01 Mb target region). 136 patient 
DNA samples were collected for performance and application testing. Panel sensitivity and precision 
were measured using well-characterised DNA controls (n = 47), and specificity by Sanger sequencing 
of the Aryl Hydrocarbon Receptor Interacting Protein (AIP) gene in 89 patients. Assessment of liquid 
biopsy application employed a pool of synthetic circulating tumour DNA (ctDNA). Library preparation 
and sequencing were conducted on Illumina-based platforms prior to analysis with our accredited 
(ISO15189) bioinformatics pipeline. We achieved a mean coverage of 395x, with sensitivity and 
specificity of >99% and precision of >97%. Liquid biopsy revealed detection to 1.25% variant allele 
frequency. Application to head and neck tumours/cancers resulted in detection of mutations aligned to 
published databases. In conclusion, we have developed an analytically-validated panel for application 
to cancers of disparate types with utility in liquid biopsy.
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Next generation sequencing (NGS) has revolutionised our understanding of cancer. New taxonomies defined 
by molecular features rather than tissue of origin are emerging as powerful tools to better diagnose and treat 
cancers, and are becoming routine clinical practice in oncology and pathology1,2. The unprecedented success of 
gene- or genetic pathway-targeting therapies such as imatinib3,4, gefitinib5,6 and trastuzumab7 over a decade ago 
was arguably the driving force behind this re-classification of cancer, with 75.6% of United States-based oncolo-
gists now using NGS to guide treatment decisions8. While whole exome/genome sequencing remains largely cost 
prohibitive9,10, targeted gene panels have proliferated in mainstream clinical care due to their relative affordability 
and focused application; allowing for simplified data interpretation by omitting less-relevant genes and reducing 
the number of variants of unknown significance, and increased depth of coverage to improve detection sensitiv-
ity9,11,12. While to date, standardised validation criteria for diagnostic accreditation do not exist due to the lack of 
uniformity across the multitude of NGS platforms and within NGS processes13, stringent validation guidelines 
have been published to provide standardised frameworks for clinical genetic tests11,14,15. Transparency in the liter-
ature has promoted the detailing of targeted panels’ development and validation across a variety of diseases, and 
highlighting their sensitivity, specificity and precision9,16–18; factors viewed as paramount for enabling clinicians 
to make important clinical management and treatment decisions19.
In oncology, targeted panels have been developed for detecting hereditary cancer, monitoring somatic changes 
in progressive cancer, and importantly for elucidating the landscape of genetic aberrations that occur across 
multiple cancers, and using this information to identify novel therapeutics or repurpose existing ones8,19–21. In 
a landmark study in 2013, Frampton et al.22 identified clinically-actionable mutations in 76% of 2221 tumours 
studied; a 3-fold increase in drug-actionable detection as compared with contemporary diagnostic tests including 
Sanger sequencing, mass spectrometric genotyping, fluorescent in situ hybridisation and immunohistochemistry. 
As an example of therapeutic repurposing, the HER2-amplified breast cancer treatment trastuzumab (Herceptin) 
has been shown to be effective in advanced gastric cancer, and potentially HER2 amplified pancreatic ductal 
adenocarcinoma23,24.
Targeted gene panels are now also being produced for liquid biopsy and ctDNA sequencing; an emerging tool 
that holds promise to monitor for cancer initiation or relapse, tumour burden and evolution including the onset 
of treatment resistance25–28. Unlike standard surgical-core biopsies, liquid biopsies can be performed repeatedly, 
non-invasively, and are not spatio-temporally constrained, that is, results reflect all individual tumour mutations 
in real-time; thus informing the broadest range of therapeutic options available.
In a preliminary study, we recently applied a targeted gene sequencing panel to 44 patients with familial pitu-
itary tumour syndromes (FPTS) and detected rare germline variants across the 8 analysed genes (AIP, MEN1, 
CDKN1B, PRKAR1A, SDHA, SDHB, SDHC, SDHD) in 11 patients29. Recognising the utility of this approach to 
poorly studied cancers, we hypothesised herein that further developing, expanding and validating our targeted 
gene panel would benefit patients with other cancers of the head and neck, and beyond. We therefore aimed to 
re-access our extended FPTS cohort, and expand our panel by adding hundreds of known cancer-associated 
genes, validate its sensitivity, precision and specificity against several well-characterised controls, and then apply 
it to two patient cohorts with oral and cutaneous squamous cell carcinoma of the head and neck (OSCC and cSCC 
respectively). We also aimed to determine our panel’s utility in liquid biopsy by targeting known mutations in 
genes at decreasing variant allele frequencies (VAFs), in a commercially available synthetic standard.
Methods
patients. DNA samples were obtained from patients with the following conditions: FPTS [n = 38 (blood-de-
rived) and 10 (tumour-derived)], sporadic pituitary tumours [n = 10 (blood-derived) and 6 (tumour-derived)], 
OSCC [n = 39 (tumour-derived)], cSCC [n = 26 (tumour-derived)], miscellaneous [n = 3 adrenocortical carci-
noma (1 blood-derived and 2 tumour-derived), 4 pancreatic ductal carcinoma (3 blood-derived and 1 tumour-de-
rived)]. Informed consent had been provided, and prior ethics approval obtained through St Vincent’s Hospital 
Sydney Human Research Ethics Committee, NSW, Australia (FPTS, sporadic pituitary tumours and adrenocor-
tical carcinomas; protocol X13-0109), and Royal Prince Alfred Hospital, NSW, Australia (OSCC, cSCC and pan-
creatic ductal carcinomas; protocols X13-0417, LNR/13/RPAH/582 and HREC/11/RPAH/329). All experiments 
were performed in accordance with relevant guidelines and regulations.
Development of the cancer gene sequencing panel PV1 and PV2. Two methods were used for 
deciding the genetic targets of our panels. Firstly, genes were selected from the following commercially availa-
ble panels: TruSight Tumour 26 and TruSeq Amplicon Cancer Panels (Illumina), SureSeq Solid Tumour panel 
(Oxford Gene Technology), Foundation One Panel (Foundation Medicine), OncoCarta Panels Versions 1–3 
(OncoCarta) and Haloplex Cancer Research Panel (Agilent). While each of these panels except Foundation 
One target specific exons or mutational hotspots, our design incorporated the entire coding region plus 10 bp of 
flanking intron of each gene included. Secondly, considering our panel was to expand upon our previously pub-
lished FPTS data29, we searched for more pituitary tumour targets by conducting a literature search on PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed/) for genes associated with aggressive pituitary tumours, familial pitui-
tary tumours, and embryonic pituitary development. In total 312 cancer-associated genes were chosen for panel 
version 1 – PV1 (Table 1), with a target region of 0.97 Mb across 4,837 exons. The panel prototype was designed 
using the Roche/NimbleGen EZ Choice Library NimbleDesign platform [https://design.nimblegen.com/nim-
bledesign/#/ (cat #06266282001)].
Panel version 2 (PV2) was a refined design leveraging off PV1 data to include more probes to improve read 
depth over poorly covered regions, plus incorporate the coding region (and 10 bp flanking intron) of 139 new 
genes (Table 1) associated with pituitary tumours and pituitary function; acquired through further PubMed lit-
erature search and clinical consultation. The target region of PV2 was 2.01 Mb, for a total of 6,929 target exons 
and 451 genes.
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We used 80 and 111 DNA samples to measure the performance metrics for PV1 and PV2 respectively (see 
Bioinformatics below). These comprised 31 samples from the patient cohorts, 6 extracted DNA samples from 4 
cancer cell lines (liposarcoma 94T778, breast cancer SK-BR-3, and melanoma SK-MEL-28 and A375), and 43 
control samples for PV1; and 105 samples from the patient cohorts and 6 controls for PV2.
controls. Several controls were obtained to test the ability of PV1 and PV2 to detect well-characterised single 
nucleotide variants (SNVs), small insertions and deletions (indels) and copy number variants (CNVs): (1) 42 con-
trols from breast cancer patients with known inherited mutations in 11 genes (Supplementary Fig. S1). We only 
retained controls that kConFab reviewed and classified/endorsed (n = 35) to test kit sensitivity; (2) an AcroMetrix 
Oncology Hotspot Control (Thermo Fisher Scientific, cat #969056), which consists of a pool of synthetic oligos 
against a normal genomic DNA background encompassing 521 somatic and 34 germline mutations in 53 genes 
(Supplementary Fig. S1); (3) a pair of DNA controls for testing our panel’s sensitivity to CNVs was derived from 
the well-characterised breast cancer cell lines SK-BR-3 and BT-474; (4) four controls from individuals NA12878, 
NA24385, NA24149 and NA21143 (Coriell Institute, NJ, USA), whose genomes have been deeply characterised 
using 12 technologies used to calibrate, benchmark and validate genomic tools for clinical practice worldwide30. 
The kConFab controls, the cell lines and the AcroMetrix Oncology Hotspot Control were tested on PV1.
ABL1 BLM CENPE EPAS1 FLT4 IKZF1 MAP3K1 NFE2L2 PIK3R2 RYR1 SUFU
ACTN4 BMP4 CGA EPCAM FOXA1 IL7R MAP3K20 NFKBIA PMS2 S100A9 SUPV3L1
ADAMTS6 BMP8 CHD1 EPHA3 FOXL2 INHBA MAPK2 NGN2 POMC SDHA TBXAS1
ADAMTS7 BMPR1A CHD7 EPHA5 FSHB IRF4 MAST4 NKX2-1 POU1F1 SDHAF2 TCF7L1
ADBRK2 BMPR2 CHEK1 EPHB1 GADD45B IRS2 MAX NKX3-1 PPP2R1A SDHB TERT**
AHR BRAF CHEK2 EPBH2 GADD45G JAK1 MCC NME1-NME2 PRB3 SHDC TESC
AIP BRCA1 CHRM3 ERBB2 GATA1 JAK2 MCL1 NOTCH1 PRDM1 SDHD TET2
AKT1 BRCA2 CIC ERBB3 GATA2 JAK3 MDM2 NOTCH2 PRDM2 SETD2 TFG
AKT2 BRIP1 CITED1 ERBB4 GATA3 JPH2 MDM4 NOTCH3 PRDM8 SF3B1 TGFBR2
AKT3 BTK CLDN11 ERG GID4 JRK MED12 NPM1 PRDX2 SHH TH
ALK C2CD3 COX2 ESR1 GLI2 JUN MEF2B NR0B1 PRKAA2 SIRT1 TMEM43
AMER1 CACNA1H CREBBP ESR2 GNA11 KAT6A MEN1 NR2C2 PRKAR1A SIX3 TMEM127
ANOS1 CACNA1S CRKL EZH2 GNA13 KCNA5 MET NR3C1 PRKDC SIX6 TNFAIP3
AOX1 CAPN1 CRLF2 FAM46C GNAQ KDM5A MGAM NRAS PRLR SKI TNFRSF14
APC CARD11 CRMP1 FANCA GNAS KDM5C MGMT NTR3 PROCA1 SLIT2 TOP1
AR C8FB CSF1R FANCC GNRHR KDM6A MITF NTKR1 PROP1 SMAD2 TOP2A
ARAF CBL CTCF FANCD2 GPR101 KDR MLH1 NTRK2 PTCH1 SMAD4 TP53
ARFRP1 CCAR2 CTNNA1 FANCE GPR124 KEAP1 MLL1 NTRK3 PTEN SMARCA4 TPM3
ARID1A CCNB1 CTNNB1 FANCF GREM1 KIAA0226 MLL2 NUP93 PTPN11 SMARCB1 TPM4
ARID2 CCND1 CXADR FANCG GRIN1 KIAA0363 MLL3 OCLN PTTG SMO TRIOBP
ARMC5 CCND2 CYP19A1 FANCL GRIN2A KIF1B MMP2 OGDH PYCR1 SNAP25 TSC1
ASXL1 CCND3 CYP2D6 FANCM GRIN2B KIT MMP9 OR51B4 RAB18 SNIP1 TSC2
ATAD2B CCNE1 CYP21A2 FBXO4 GSK3B KLHL6 MMP17 OSBP RAB1A SNX3 TSHB
ATM CCR10 DAXX FBXW7 HESX1 KRAS MPL OTX2 RAC1 SOCS1 TSHR
ATP6V0A1 CD79A DBF4 FGF2 HGF LATS2 MRE11A PAK3 RAD50 SOCS2 UBR4
ATPAF2 CD79B DCAMKL3 FGF3 HIF1α LGALS3 MSH2 PALB2 RAD51 SON UCP3
ATR CDC2L2 DDR2 FGF4 HMGA1 LHB MSH6 PALLD RAD51C SOS1 UGT1A1
ATRX CDC73 DDX3× FGF6 HMGA2 LHX2 MTOR PARP10 RAD51D SOX2 UGT2B7
AURKA CDH1 DICER1 FGF8 HMGB1 LHX3 MUTYH PAX5 RAF1 SOX3 USP8
AURKB CDK3 DMD FGF10 HNF1A LHX4 MX2 PAX6 RARA SOX9 VEGFA
AXL CDK4 DNMT3A FGF14 HNRPU LOXL1 MYC PAX7 RARS SOX10 VHL
BAP1 CDK6 DOC1 FGF19 HOXB13 LRP1B MYCL1 PBRM1 RASA4 SPANXN2 WIF1
BARD1 CDK8 DOT1L FGF23 HPGD LRP2 MYCN PCDH11X RB1 SPEN WISP3
BAX CDK12 DPCR1 FGFR1 HRAS LRRC50 MYD88 PDGFD RET SPOP WNT4
BBC3 CDKN1A DSPP FGFR2 HSP90AA1 LTBP4 MYO5A PDGFRA REXO4 SPTA1 WNT9A
BCL2 CDKN1B DST FGFR3 IDH1 MAG NBN PDGFRB RICTOR SRC WT1
BCL2L2 CDKN2A (p14ARF)* EGF FGFR4 IDH2 MAN1A1 NCAM1 PDK1 RNF43 SRP9 XPO1
BCL6 CDKN2A (p16)* EGFL7 FH IGF1R MAP1LC3B NDRG4 PIK3CA RPA1 SSR3 ZFHX3
BCL9 CDKN2B EGFR FLNA IGFBP5 MAP2K1 NF1 PIK3CB RPTOR STAG2 ZNF217
BCOR CDKN2C EGLN1 FLT1 IGSF1 MAP2K2 NF2 PIK3CG RUNX1 STAT4 ZNF703
BCORL1 CEBPA EMSY FLT3 IKBKE MAP2K4 NFE2L1 PIK3R1 RXRG STK11 ZNF717
Table 1. Genes targeted in Panel Version 1 and added to Panel Version 2 (bold). *Two protein coding isoforms 
were targeted of the same gene. **Including promoter region.
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Two repeat kConFab control samples and a repeat of the AcroMetrix Oncology Hotspot Control where 
expected mutations were missed in PV1 due to lack of coverage, and the Coriell samples were tested on PV2.
Panel specificity testing. Routine clinical practice in St Vincent’s Hospital’s Department of Endocrinology 
for patients with suspected FPTS, includes Sanger sequencing of the AIP gene. Sanger sequencing is required 
for panel specificity validation, as it verifies true negatives, that is, it confirms that alleles labelled as wild type 
by next generation sequencing panels, are truly wild type and not mutated as previously defined18. We accessed 
the Sanger sequencing data for 89 FPTS patients who had been sequenced with our panels for this study, and the 
aforementioned preliminary study29.
Liquid biopsy for ctDNA. To test for the applicability of our panel to liquid biopsy, we acquired synthetic 
oligos of analogous lengths to ctDNA, representing 9 known mutations across 6 cancer-associated genes (Seraseq 
Circulating Tumor DNA (ctDNA) Reference Material, SeraCare Life Sciences, MA, USA; cat #0710-0018). The 
mutated oligos were provided at different allelic frequencies (5%, 1.25%, 0.625%, 0.125% and 0%) in a matrix 
containing human proteins to closely resemble human plasma.
NGS library preparation and sequencing. Genomic DNA. Genomic germline DNA was extracted from 
peripheral blood leukocytes using the QIAamp DNA Blood Midi Kit (Qiagen; cat #51183), or from fresh-frozen 
tumour samples using Qiagen’s DNeasy kit (cat #69504), through Garvan Molecular Genetics. DNA library 
preparation for all PV1 samples was conducted on 100 ng of input using the KAPA Hyper Library Preparation 
Kit (Roche, cat #KK8504), according to manufacturer’s instructions. For PV2, library preparation was conducted 
using the KAPA HyperPlus Kit (Roche, cat #KK8514) according to manufacturer’s instructions. KK8514 uses 
enzymatic digestion rather than sonication to fragment genomic DNA as per KK8504.
NGS was performed using Illumina’s HiSeq2500 for all samples in multiplexed pools of 17–24/lane.
ctDNA. Libraries were prepared using the QIAseq Ultralow Input Library Kit (Qiagen; cat #180495), according 
to manufacturer’s instructions. Oligos were captured with PV1 and sequenced on Illumina’s NextSeq500 platform 
in multiplexed pools.
Bioinformatics. Our bioinformatics pipeline had been accredited for Medical Testing (ISO15189) by the 
National Association of Testing Authorities, Australia (NATA)/Royal College of Pathologists of Australasia 
(RCPA) in 2016. In brief, raw fastq files were transferred to the cloud-based genomic analysis platform DNAnexus 
(www.dnanexus.com). Bioinformatic read alignment and improvement, variant annotation, conversion, filtra-
tion and prioritisation were conducted as previously published31–33; the exception being for ctDNA where read 
duplications were not marked. Germline and somatic variants were called using the Genome Analysis Toolkit’s 
(GATK) HaplotypeCaller (v3.3) in GVCF mode34 and VarDictJava (v1.4.6)35 respectively. Copy number variants 
occurring across entire genes was determined using CNVkit (v0.9.1)36, and within genes using DECoN37.
Panel performance metrics including number of total reads, number of unique reads, mean coverage across 
regions captured by each panel version and targeted genes specifically (RefSeq coding exons), read enrichment 
and read duplication were assessed using the GATK’s CollectHsMetrics (Picard) and DepthofCoverage tools. By 
using controls with well-characterised SNVs, indels and CNVs, we were able to measure the sensitivity and/or 
precision of PV1 and PV2 as previously defined18. To measure precision recall and sensitivity for the four Coriell 
samples, we added a hard filter step recommended by GATK for small panels and then applied vcfeval in RTG 
Tools38.
Statistics. Statistical analysis was performed using R (v3.6). Differences between groups were measured by 
ANOVA and identified using post-hoc Tukey’s HSD test. For the comparison between two groups, t-test was 
employed. p < 0.05 was used to determine if results were significantly different.
Results and Discussion
performance evaluation. The mean total number of reads between PV1 and PV2 were similar at approx-
imately 22.5 M (Supplementary Table S1), however the total number of unique reads for PV2 was nearly double 
that of PV1 (p < 0.001), consistent with the significantly lower PCR duplication rate in PV2 (p < 0.001) (Fig. 1A).
We achieved the vendor performance recommendations for both PV1 and PV2 designs, with a mean depth of 
coverage across regions captured by each panel version of >100x and a mean percent of captured bases covered 
at >20x across panel versions of ≥95% (Supplementary Table S1). While mean depth of coverage and percent 
bases with >100x coverage were not significantly different between PV1 and PV2 (Fig. 1A), greater variability was 
observed for PV1 for percent bases with >20x coverage, with a mean significantly lower than for PV2 (p < 0.001) 
(Fig. 1A). We then evaluated how well the designed probes covered the actual exons of targeted genes. As men-
tioned previously, exons identified with low coverage in PV1 were balanced with more probes in PV2. The result 
was an increase in the mean depth of coverage across the targeted genes shared between the panels, from 351x 
(PV1) to 460x (PV2) (Fig. 1B), and at individual gene level, the mean depth of coverage across samples was con-
sistently >100x in PV2 but not in PV1 (Fig. 1C). If we take into consideration the full PV2 design, which includes 
an additional 139 genes, the global mean gene depth of coverage for this panel version was 395x (Fig. 1D) and the 
mean percent of targeted bases across genes with > 100x coverage was 84% (Fig. 1E).
Overall the performance of PV2 was an improvement upon PV1. Our panel far exceeds the typical 30x cov-
erage recommended by providers of whole genome sequencing for germline analyses, and the 100x coverage 
recommended for somatic variant detection.
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Sensitivity assessment. kConFab. 42 DNA samples from patients with mutations of various types in 
11 genes were acquired from kConFab (Table 2, Supplementary Fig. S1), with the 35 that had been classified 
and reviewed proceeding through to library preparation and analysis. We detected 34 of the expected mutations 
(Table 2). The undetected variant, BRCA1 c.135-1G > T, had been identified in the donor by two different clinical 
Figure 1. Performance metrics for PV1 and PV2. (A) Box plots presenting data comparisons between PV1 
(n = 80 samples tested) and PV2 (n = 111 samples tested) for unique reads (in millions; M), percent duplication, 
target coverage and percent base coverage at >20x and >100x. (B) Mean coverage over coding regions of shared 
genes was compared between PV1 and PV2 after additional probes to target poorly-covered regions were added 
to the latter. (C) Changes to individual shared targets between PV1 and PV2 are also presented. (D) The final 
mean coverage for PV2 is presented following the addition of 139 new genes for a total of 451 targeted genes, as 
well as (E) the final percentage of targeted coding bases in PV2 with a percent mean coverage of >100x. Dashed 
lines in panels (B–E) represent mean coverage. ***p < 0.001, ns = not significant.
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laboratories plus a research laboratory, and appeared to segregate with 12 other family members being affected. 
Our data however raises the potential of an annotation error, or potential sample swap, with just one read on 
the Integrative Genomics Viewer (IGV)39 exhibiting the mutation against a backdrop of ~1200 wild type reads 
of excellent mapping quality (Supplementary Fig. S2A). Two other potential annotation errors were observed 
among the detected variants (Table 2). Firstly, we detected BRCA1 c.3193_3194dupG, p.Asp1065Glyfs*2, but it 
had been reported as c.3194_3195insG, p.Asp1065Glufs * 2 by clinical and research laboratories across numerous 
family members (Supplementary Fig. S2B). Secondly, we detected insertion BRCA1 c.1879_1880insCC, result-
ing in a p.Val627Alafs*6 change (Table 2 and Supplementary Fig. S2C) instead of c.1881_1882_insCC, p.Ser-
628Profs*5 that was recorded by other laboratories. Next generation sequencing does have difficulties resolving 
indels in highly repetitive or homopolymer regions, as well as regions of high A-T and G-C content15, however 
the regions in Supplementary Fig. S2B,C do not appear to be problematic. As per the ‘undetected’ variant above, 
mapping quality for these two potential annotation errors was excellent, and excellent depth was achieved over 
both wild type and inserted alleles, providing confidence in our calls.
Two of the expected events, BRCA1 exon 13 duplication (Fig. 2A) and CHEK2 c.444 + 1G > A (Supplementary 
Fig. S3A), were only detected using PV2 after not being detected in PV1. This adds to the evidence of improved 
coverage in PV2 described above. In addition to the BRCA1 duplication, two other expected multi-exonic dupli-
cations were successfully detected in MSH2 and TP53 using DECoN (Fig. 2A, Table 2).
Chr Pos Ref Alt
Mut 
type Gene Detected CDS Detected AA Detection
VAF 
(%)
2 47702181 C T SNV MSH2 c.1777C > T p.Gln593Ter D 48
2 DUP MSH2 Exon 9-11 duplication D
2 215645969 GTT G DEL BARD1 c.627_628delAA p.Lys209Asnfs*4 D 51
9 97912356 G A SNV FANCC c.535C > T p.Arg179Ter D 53
9 98011506 TC T DEL FANCC c.67delG p.Asp23Ilefs D 49
10 89690810 G T SNV PTEN c.217G > T p.Glu73Ter D 56
10 89692818 TCA CC CV PTEN c.302_304delTCAinsCC p.Ile101Thrfs*12 D 47
10 89692904 C T SNV PTEN c.388C > T p.Arg130Ter D 49
11 108165787 G A DEL ATM c.4909 + 1G > A p.Met297_Ser301del D 49
13 32913708 ATTAAGT A DEL BRCA2 c.5217_5223delTTTAAGT p.Tyr1739Terfs D 53
13 32913778 T A SNV BRCA2 c.5286T > A p.Tyr1762Ter D 45
13 32914174 C G SNV BRCA2 c.5682C > G p.Tyr1894Ter D 50
13 32937635 AC A DEL BRCA2 c.8297delC p.Thr2766Asnfs*11 D 52
13 32954180 C T SNV BRCA2 c.9154C > T p.Arg305Trp D 51
15 91328183 C T SNV BLM c.2695C > T p.Arg899Ter D 44
16 23632683 C T SNV PALB2 c.3113G > A p.Trp1038Ter D* 45
16 23632683 C T SNV PALB2 c.3113G > A p.Trp1038Ter D* 42
16 23634303 CA CAA INS PALB2 c.2982dupT p.Ala995Cysfs*16 D 43
16 23641239 CT C DEL PALB2 c.2235delA p.Lys745Lysfs * 19 D 51
16 23641528 CT C DEL PALB2 c.1947_1948insA p.Glu650Argfs * 13 D 44
17 7577539 G A SNV TP53 c.742C > T p.Arg248Trp D 53
17 7578406 C T SNV TP53 c.524G > A p.Arg175His D 39
17 7578552 G T SNV TP53 c.378C > A p.Tyr126Ter D 45
17 7674945 G A SNV TP53 c.586C > T p.Arg196Ter D 52
17 DUP TP53 Exons 2–6 duplication D
17 41197774 A T SNV BRCA1 c.5513T > A p.Val1838Glu D 49
17 41197784 G A SNV BRCA1 c.5503C > T p.Arg1835Ter D 47
17 41243788 TAGAC T DEL BRCA1 c.3756_3759delGTCT p.Ser1253Argfs * 10 D 52
17 41244353 A AC INS BRCA1 c.3193dupG p.Asp1065Glyfs * 2 D# 52
17 41245666 T TGG INS BRCA1 c.1879_1880insCC p.Val627Alafs * 6 D# 45
17 41246260 C CT INS BRCA1 c.1287dupA p.Asp430Argfs * 6 D 45
17 41258551 C A SNV BRCA1 c.135-1G > T p.Phe46_Arg71del ND§
17 DUP BRCA1 Exon 13 duplication D†
22 29095862 AG A DEL CHEK2 c.1100delC D 50
22 29121230 C T SNV CHEK2 c.444 + 1G > A p.Thr367Metfs D† 41
Table 2. Detection of kConFab variants. Abbreviations: AA; Amino acid, Alt; Alternative, CDS; Coding 
sequence, Chr; Chromosome, CV; Complex variant, D; Detected, Del; Deletion, Dup; Duplication, INS; 
Insertion, Mut; Mutation, ND; Not detected, Pos; Position, Ref; Reference, SNV; Single nucleotide variant, VAF; 
Variant allele frequency. *The same variant was expected in two samples. #Reported in kConFab depository as 
c.3194_3195insG, p.Asp1065Glufs * 2 and c.1881_1882insCC, p.Ser628Profs * 5 respectively. §Visible as a single 
read against ~1200 wild type reads on Integrative Genomics Viewer. †Detected on PV2 only.
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Acrometrix oncology hotspot control (synthetic oligos). PV1 detected 97% (n = 538) of the 555 expected muta-
tions of various types across 53 genes (Supplementary Fig. S1, Supplementary Table S2) in the synthetic oligos. 
This included 98% of the somatic variants at 5–15% VAF, 97% of the somatic variants at 15–35% VAF, and 97% of 
Figure 2. Intragenic copy number detection and comparison to commercial panels. (A) Control genomic 
DNA samples were acquired from kConFab for sensitivity testing. Three of these samples included known exon 
duplications in BRCA1, TP53 and MSH2, which were assessed by the DeCON tool. Exons are numbered along 
the x-axis, and those of normal copy number are presented as blue dots. Amplifications are shown in red. The 
TP53 and AURKB genes are on opposing DNA strands hence the presence of the latter and its exons in this 
Figure. A similar genetic-overlap is observed for MSH2 to the left of the panel. (B) A commercially available 
pool of synthetic oligos against a normal genomic background was also obtained. Mutations were provided at 
variant allele frequencies (VAF) of 5–15% and 15–35%, or at germline frequencies. Presented are the number 
of detected and missed variants in our PV1 and PV2 panels relative to what was expected in AcroMetrix. This 
was compared to three other panels [AmpliSeq Cancer Hotspot Panel v2 (CHPv2), Illumina TruSeq Amplicon 
– Cancer Panel (TSCAP) and TruSight Tumor Panel 26 (TSTP)], the data for which were provided by the 
AcroMetrix manufacturer. Percent values on the right indicate the proportion of AcroMetrix variants actually 
targeted by the panels.
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germline variants. The addition to PV2 of new probes to cover poorly or non-targeted regions, greatly improved 
sensitivity, such that 553 (99.6%) of the expected mutations were detected (Figs. 2B and S3B). In comparison 
to the three other commercial sequencing panels presented in Fig. 2B, our panel had greater breadth, targeting 
Figure 3. Copy number evaluation in breast cancer cell lines. (A) Heat map representation of ~300 targeted 
genes in the SK-BR-3 and BT-474 breast cancer cells lines. Data was extracted from PV1-captured DNA and 
processed through CNVkit and compared to those expected according to the Broad Institute’s Cancer Cell Line 
Encyclopedia (CCLE). Copy number deletions are represented in blue and as copy numbers approach diploidy 
colours become white. Amplification in copy number is represented in red. (B) Regression analysis was carried 
out using the correlation coefficient to quantify the strength of relationship between PV1 called variants in 
SK-BR-3 and (C) BT-474, and those expected according to CCLE. An r-value of >0.7 is considered a strong, 
positive relationship. (D–G) Ten lowest (red) and ten largest CNV (blue) changes as detected by PV1 in SK-
BR-3 (D) and BT-474 (F). These were compared to expected values according to CCLE (E,G). Note the log2 
y-axes and the gene names on the x-axes. Complete data is presented in Supplementary Fig. S4.
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100% of the AcroMetrix oligo pool, and greater sensitivity, detecting proportionally more expected variants, with 
AmpliSeq Cancer Hotspot Panel v2 (CHPv2), Illumina’s TruSeq Amplicon – Cancer Panel (TSCAP) and TruSight 
Tumor Panel 26 (TSTP) detecting 98.8%, 97.1% and 97.4% of their respective targets.
With respect to the missed variants using PV2, both of which were expected at low VAFs (5–15%); the HNF1A 
c.872_873insC, p.G292fs*25 change, occurred in a highly repetitive region involving a poly-C tract, possibly 
creating alignment difficulties15 (Supplementary Fig. S3C). This is supported by the insertion being placed either 
side of the guanine nucleotide as shown in the top and bottom IGV panels of Supplementary Fig. S3C. Potentially 
compounding difficulties with this particular call, was the presence of HNF1A variant c.864G > C, p.G288G in 
the background genomic DNA. This variant was detected by both HaplotypeCaller and VarDict in both panel 
versions, with the former occasionally calling the correct insertion in PV1 at the same time. Consistent with this 
potential interference of accurate calling, was a large somatic indel (in addition to the substitution) called by 
VarDict in PV2 at position c.866_914. Thus in a real patient we may accurately identify c.872_873insC. We did 
detect all other expected indels and hence this is not an intrinsic issue with PV2. Our inability to detect PIK3CA 
c.1633G > A, p.E545K might reflect the threshold of detection of VarDict, since the variant was observed on IGV 
with 3.8% VAF (8/209 reads). However, this mutation occurs at a hotspot, with three other nearby mutations in 
cis all detected at the same VAF (Supplementary Fig. S3D).
Thus, while PV2 will not detect 100% of expected variants, its sensitivity of >99% is comparable to commer-
cially available panels. Further, our ability to detect SNVs and indels at various VAFs confirms that our achieved 
coverage is sufficient for application to somatic cancer analyses. Nonetheless, we next investigated which variants 
of known clinical significance our panel would have difficulty detecting, using two well established databases; 
(i) ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), a catalogue of genomic variation and (ii) the Catalogue Of 
Somatic Mutations In Cancer (COSMIC; https://cancer.sanger.ac.uk/cosmic). Based on the literature, 20–30x 
coverage is sufficient for the detection of germline variants15,40. Assessment of our targeted regions which 
recorded mean depths of coverage of <20x, revealed that five targeted mutations of clinical significance in the 
ClinVar database, would be poorly covered and may not be identified (Supplementary Table S3). These five var-
iants all occurred across three alleles within the same targeted region of the LHB gene. With respect to detect-
ing somatic variants, 100x coverage is sufficient for detecting 80% of expected variants in tumour tissue of at 
least 55% purity40,41. Using 100x as a cut off, 158 targeted mutations encompassing 137 alleles in 23 genes in the 
COSMIC database may be missed in tumours of lower purity (Supplementary Table S3). These somatic alleles fall 
under 30 targeted regions of our panel, which when added to the poorly covered region identified in the ClinVar 
comparison, amounts to <0.5% of the total targeted region of our panel. Improvements could be made in future 
iterations of our panel design to compensate for these very few insufficiencies, or greater amounts of highly pure 
input DNA could be used at initial library preparations when searching for variants in these regions using PV2.
Control cell lines. We applied PV1 to breast cancer cell lines SK-BR-3 and BT-474. Both are well character-
ised with respect to CNVs, and fully annotated data is available through the Broad Institute’s Cancer Cell Line 
Encyclopedia (CCLE; https://portals.broadinstitute.org/ccle/data)42. Heat map analysis qualitatively revealed 
large concordance between PV1 detected amplifications and deletions, with those expected in the CCLE data 
for both cell lines (Fig. 3A). These were confirmed quantitatively through regression analysis, with correla-
tion coefficients of 0.79 and 0.83, demonstrating strong relationships between PV1 and CCLE in SK-BR-3 and 
BT-474 respectively (Fig. 3B,C). The top ten deletions and amplifications detected by PV1 compared well to 
those expected according to CCLE in both cell lines (Fig. 3D–G), with notable deletions including CDKN2A and 
CDKN2B, and notable amplifications in ERBB2, CDK12 and MYC. The data highlight the utility of our panel in 
detecting larger CNVs, with all detected and expected deletions (copy number <1.5) and amplifications (copy 
number >2.5) presented in Supplementary Fig. S4. It is also noteworthy that our panel detected 100% of the 
expected SNVs and indels in both cell lines (data not shown).
Coriell controls and specificity. As previously stated, the four genomes originally sourced from the Coriell 
Institute have been extensively characterised by 12 NGS technologies and are used as benchmarks for validation. 
As per our sensitivity controls above, our panel detected known variants with a sensitivity of >99% in all four 
samples (Table 3). Precision, which is a measure of reproducibility, was at >97% in all four samples.
The third essential parameter for validation is specificity, which relies on ‘true negative’ detection, such that a 
second technology, usually Sanger sequencing, is employed for verification. We did not use Sanger sequencing on 
Sample
True positive 
(TP)
False positive 
(FP)
True negative 
(TN)
False negative 
(FN) Precision** Sensitivity*** Specificity****
NA12878 602 16 ND 4 0.974 0.993 ND
NA23485 562 13 ND 1 0.977 0.998 ND
NA24149 580 11 ND 1 0.981 0.998 ND
NA24143 552 12 ND 2 0.979 0.996 ND
AIP* 13 0 88,377 0 1.000 1.000 1.000
Table 3. Sensitivity and precision in well characterised genomes, and specificity measure. Abbreviations: ND; 
Not done. *AIP gene (993 bp) was Sanger sequenced in 89 FPTS samples alongside application of PV1 and PV2. 
**Precision calculated by TP/(TP + FP). ***Sensitivity calculated by TP/(TP + FN). ****Specificity (AIP only) 
calculated by TN/(TN + FP).
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our four Coriell samples. However, as stated, Sanger sequencing data was available for AIP screening from 89 FPTS 
patients also screened on our panel. All bases called as wild type in AIP using our panel, were shown to be true, pro-
viding a specificity value for our panel of 100% (Table 3). This is comparable to current commercially available panels. 
Given we only tested one gene which encompasses a target region much smaller than the panel in its entirety (~1 kb), 
one could reasonably speculate that when taking the whole panel into account, that specificity may drop. However, 
given the extremely low numbers of false positives and false negatives relative to true positives detected across the 
entire panel (Table 3), we expect that true negatives will be proportionately high, and that any change in specificity 
would be negligible. Further, our data for true negatives in AIP was reproducible across a large number of patients.
Application of PV2 to FPTS, OSCC and cSCC samples. Following validation, we tested our ability to 
detect rare variants (≤1% occurrence in control populations) in three cohorts of patients with different tumour 
Figure 4. Rare variants are detectable in FPTS, OSCC and cSCC samples, at a similar ratio to online databases. 
Our validated panel was applied to cohorts of patients with FPTS (n = 18) (A), OSCC (n = 39) (B), and cSCC 
(n = 27) (C), for the detection of rare (≤1% control population) variations of various categories. Data for OSCC 
and cSCC was compared to TCGA and Pickering/Inman databases51,53, with genes arranged in order of most 
commonly mutated within those databases. Variants were restricted to high and medium impact. No such 
database exists for pituitary tumours, and genes were restricted to the 8 described in FPTS. Variants of any 
impact were included in the data presented herein for FPTS.
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types of the head and neck. Pituitary adenomas are common, with 1:1000 patients presenting with clinically 
significant disease29,43. They are classically associated with gross morbidity encompassing the effects of excess hor-
mone production, vision loss, osteoporosis, diabetes, cardiovascular disease, infertility and disfigurement among 
others, but their low mortality in general has contributed to poor molecular classification44; unlike for OSCC and 
cSCC below, no extensive online databases are available for pituitary tumours.
Germline variants in eight genes have been associated with FPTS (AIP, MEN1, CDKN1B, PRKAR1A, SDHA, 
SDHB, SDHC and SDHD)29, and as the occurrence of pathogenic variants is low and we assessed just 18 patients, 
we included variants of predicted low significance in our data presented herein. SNVs and indels occurring within 
exons, introns, splice sites and untranslated regions (UTRs) were successfully detected across the genes, except in 
SDHD (Fig. 4A). Coverage of this gene was a high 479x and hence we postulate that the lack of variants detected 
was due to the low sample numbers and mutation rarity. Indeed in our previously published data in 44 FPTS 
patients using the developmental version of this panel, just one predicted benign variant was detected in SDHD29.
The data presented for our tumour cohorts of OSCC (n = 39; Fig. 4B) and cranio-facial cSCC (n = 24; Fig. 4C), 
includes variants of high and medium impact only. 8% of worldwide malignancies are mucosal head and neck 
squamous cell carcinomas, which represent a heterogeneous group of malignancies including OSCC45. OSCC 
is classically associated with alcohol and tobacco abuse in older men46. cSCC is associated with UV-induced 
DNA damage due to sunlight exposure47. Its incidence is poorly defined48, though like for OSCC, it is increasing. 
Prognosis is poor for OSCC and also for the <5% of cSCC that is metastatic to regional lymph nodes49–52. Genetic 
stratification for both tumours is improving; for OSCC on The Cancer Genome Atlas (TCGA; a collection of 
>20,000 extensively-characterised primary tumours spanning 33 cancer types) and for cSCC in the literature51,53.
The genes presented in Fig. 4B,C are ordered according to their mutation rate in TCGA and Pickering et al.51 
and Inman et al.53. Our panel identified mutations in these genes at a similar order of occurrence in our cohorts. 
The exception is for CACNA1C in cSCC which was not targeted by PV2. Consistent with our panel validation 
data, we were able to detect mutations of various categories, and when taking into account that the TCGA and 
Pickering/Inman databases used larger cohorts than that used herein, we detected these mutation categories at 
similar proportions to the databases. Detailed analysis of these three cohorts of data will be presented elsewhere.
Application of our panel to synthetic ctDNA oligos. Having produced a panel with high sensitivity, 
precision and specificity, and having demonstrated its application to cancers of the head and neck, we tested the 
utility of our panel in liquid biopsy; an emerging tool in tumour burden monitoring and early detection of cancer 
or relapse that aids personalised medicine. The commercially available synthetic oligos used were produced at 
fragment sizes analogous to ctDNA (167 bp)54, suspended in a substrate similar to human plasma, and provided 
in aliquots of four different VAFs. We achieved a mean depth of coverage of 2,196x across the aliquots, and 
detected 8/9 and 6/9 mutations at 5.00% and 1.25% VAF respectively (Table 4). We could not detect any expected 
variants at 0.625% or 0.125% VAF (Table 4).
Shu et al.54 employed a panel of similar size to ours and detected tumour specific mutations in 87% of 605 
ctDNA samples sourced from various cancer types, with VAF >1% at 300–500x depth. Increasing depth of cov-
erage to ~2000x did not significantly alter variant-detectability54. However, in early stage cancer ctDNA can exist 
at levels around 0.1% VAF, and thus for early detection of cancer initiation or recurrence, previous studies sought 
to achieve a 10,000x coverage; a target both expensive to achieve and prone to sequencing errors and false posi-
tives54–57. New technologies have been developed to identify and reduce sequencing errors to enable ultra-deep 
sequencing of ctDNA54–59, but to aid this economically, smaller sequencing panels may need to be developed.
Early data suggest our panel’s applicability for the monitoring of established cancers shedding higher quanti-
ties of ctDNA. To detect earlier cancers, or variants in tumours known to shed less ctDNA (eg glioma and renal 
cell carcinoma)60, modifications would need to be made such as reducing the breadth of our target region to com-
mon cancer genes or to mutational hotspots, or adopting some of the new, emerging technologies54–59.
In conclusion, we have developed a targeted gene panel for application to disparate cancer types that encom-
passes 451 cancer-associated genes. The novelty of our panel is that compared to many commercially availa-
ble products, PV2 targets genes in their entirety and not just select exons or mutational hotspots. Additionally, 
our panel targets a broad range of pituitary tumour-associated genes. We validated our panel by assessing its 
Gene/mutation
5.00% VAF
(2314x mean coverage)
1.25% VAF
(2015x mean coverage)
0.625% VAF
(2091x mean coverage)
0.125% VAF
(2364x mean coverage)
BRAF; p.V600E Yes Yes No No
EGFR; p.T790M Yes No No No
EGFR; p.D770_N771insG Yes Yes No No
EGFR; p.E746_A750del Yes Yes No No
PIK3CA; p.H1047R Yes No No No
PIK3CA; p.N1068fs*4 Yes Yes No No
NRAS; p.Q61R Yes Yes No No
KRAS; p.G12D Yes No No No
KIT; p.D816V No Yes No No
Table 4. Detection of synthetic ctDNA oligos. Abbreviation: VAF; Variant Allele Frequency.
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analytical sensitivity, precision and specificity. This was achieved through application to 47 well-characterised 
controls, including 4 that are routinely used for benchmarking. Our sensitivity and specificity results were aligned 
to commercially available panels and early data suggest promise in liquid biopsy, an emerging tool in precision 
oncology. Finally, we applied our validated panel to cohorts of patients with pituitary tumours and OSCC and 
cSCC. We were able to detect variants of various categories and for OSCC and cSCC, at similar proportions to 
those expected, suggesting that our panel would be beneficial to patients with poorly studied cancers of the head 
and neck, and beyond.
Data availability
The patient-derived datasets generated here currently lack consent for genomic data sharing, and as such are not 
deposited online.
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